FIELD: medicine.
SUBSTANCE: invention concerns methods for prediction of complete morphological regressions (CMR) in the patients with triple-negative resectable breast cancer. The immunohistological analysis of tumour tissue is conducted. A regression equation Y is determined by formula: Y=7.0-4.1X1-0.15X2+1.8X3-4.8X4+1.78X5+0.56X6, wherein: X1 is a size of a primary tumour node: 1 - less than 30 mm, 2 - 30 mm and more; X2 is the state of the regional lymphatic apparatus: 0 - the absence of a metastatic lesion of the lymph nodes, 1 - the lesion involving up to 4 lymph nodes, 2 - the lesion involving 4-9 lymph nodes, 3 - the lesion involving 10 lymph nodes and more; X3 is the chemotherapy regimen: 1 - FAC, 2 - CAX, X4 is the EGFR1 expression level in the biopsy material of the tumour tissue: 1 - less than 10%, 2 - 10% and more; X5 is the Ki-67 expression level in the biopsy material of the tumour tissue: 1 - less than 20%, 2 - 20% and more; X5 is the VEGFR-2 expression level in the biopsy material of the tumour tissue: 1 - less than 70%, 2 - 70% and more. A probability of CMR is calculated by formula: P=eY/(1+eY). If P<0.5, the low probability is predicted, whereas P>0.5 shows the high probability of CMR.
EFFECT: method for prediction enables increasing accuracy and information value.
6 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PREDICTING ACHIEVEMENT OF COMPLETE MORPHOLOGICAL REGRESSIONS IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER, WHO OBTAINED CHEMOTHERAPY COURSES IN CAX REGIMEN | 2014 |
|
RU2563180C1 |
METHOD OF PREDICTING EFFICIENCY OF NEOADJUVANT CHEMICAL THERAPY IN PATIENTS WITH RESECTABLE BASAL-LIKE TRIPLE-NEGATIVE BREAST CANCER | 2013 |
|
RU2538638C1 |
METHOD FOR PREDICTION OF DEGREE OF FULL REGRESSION PROBABILITY DURING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH LUMINAL MOLECULAR-GENETIC SUBTYPE OF BREAST CANCER | 2016 |
|
RU2632112C1 |
METHOD FOR PREDICTION OF FULL REGRESSION PROBABILITY DURING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH THREE-TIMES NEGATIVE MOLECULAR-GENETIC SUBTYPE OF BREAST CANCER | 2016 |
|
RU2623118C1 |
METHOD FOR PREDICTION OF HAEMATOGENOUS METASTASIS IN TRIPLE NEGATIVE INVASIVE NON-SPECIFIC BREAST CARCINOMA | 2014 |
|
RU2558863C1 |
METHOD FOR PREDICTION OF LYMPHATIC CANCER SPREAD ACCOMPANIED BY INVASIVE NONSPECIFIC TRIPLE-NEGATIVE BREAST CANCER | 2014 |
|
RU2558860C1 |
METHOD FOR PREDICTION OF OCCURRENCE OF LOCAL RECURRENCES IN POSTOPERATIVE PERIOD IN PATIENTS WITH LOCALLY ADVANCED BREAST CANCER | 2020 |
|
RU2734719C1 |
METHOD FOR PERSONALIZED ASSIGNMENT OF NEOAJUVANT CHEMOTHERAPY TO PATIENTS SUFFERING FROM LUMINAL TYPE B BREAST CANCER | 2015 |
|
RU2594251C1 |
METHOD OF PREDICTING RESISTANCE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER | 2022 |
|
RU2802671C1 |
METHOD FOR PREDICTION OF LYMPHATIC CANCER SPREAD ACCOMPANYING NON-SPECIFIC BREAST CARCINOMA | 2014 |
|
RU2566732C1 |
Authors
Dates
2015-08-20—Published
2014-04-24—Filed